4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-23-056184
Chief R&D Officer sold 9,646 shares at $0.49 ($4,727)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-11-17 | Sale : show line 1 in the form | −9,646 | $0.49 | $4,727 | 274,039 | D |
| Open-market sales · 9,646 sh · avg $0.49 · $4,727 | ||||||
Loading xslF345X05/doc4.xml…